Intercell and Novartis's Japanese encephalitis vaccine gains EU approval
This article was originally published in Scrip
Executive Summary
Intercell and Novartis's Japanese encephalitis vaccine, Ixiaro, has received EU marketing approval for adults aged 18 and over, just three days after it was approved in the US.